TRAJ36

Across TCGA pan-cancer cohorts, TRAJ36 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TRAJ36 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TRAJ36 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAJ36 expression acts as an unfavorable survival marker.

STAD are the cancer types where TRAJ36 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.196	0.676	.008	30	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

TRAJ36–STAD (OS)

Open the STAD breakdown →